Today (August 2nd), Fortune PlusAPP released the latest Fortune Global 500 list simultaneously with the world. Affected by the new crown epidemic, the operating income of the Fortune Global 500 companies this year is approximately US$31.7 trillion, down 5% from last year. The threshold (minimum sales revenue) to enter the rankings has also dropped from US$25.4 billion to US$24 billion. At the same time, corporate profits have plummeted. The total net profit of all the companies on the list this year is 1.6 trillion US dollars, a sharp drop of 20% year-on-year, the biggest drop since 2009. Among them, it is worth mentioning that a total of 19 Pharmaceutical companies have entered the list of the top 500. China Resources, Johnson & Johnson, and China National Pharmaceutical Group ranked first, second and third respectively; revenues reached 99437.6 million US dollars. , 82584 million US dollars and 77278.2 million US dollars. In addition, there are 6 new pharmaceutical companies on the list this year, namely AstraZeneca, Boehringer Ingelheim, Guangzhou Pharmaceutical Group Co., Ltd., Amgen, Gilead Sciences, and Eli Lilly. In addition, the rankings of Bayer and Pfizer Pharmaceuticals fell to varying degrees, Bayer fell 13 places; Pfizer Pharmaceuticals fell 66 places. List and details of 19 world 500 compulsory drug companies It is particularly worth mentioning that this year, three Chinese pharmaceutical companies have been listed in the Fortune Global 500, China Resources Co., Ltd., China National Pharmaceutical Group, and Guangzhou Pharmaceutical Group Co., Ltd. Although the ranking data of China Resources Group includes statistics other than its non-pharmaceutical business, there is no doubt that both China Resources and Sinopharm are already "Big Mac" companies in China's pharmaceutical industry. China Resources Group is among the top 100 in the world, achieving double-digit growth in total profit and net profit It is reported that this year's China Resources Group's ranking has risen again and jumped to 69. Since China Resources first declared the Fortune Global 500 in 2010, the ranking has risen continuously; under the spread of the new crown epidemic, in the extremely extraordinary 2020, China Resources has also handed over. An extraordinary report card, both total profit and net profit achieved double-digit growth.
Screenshot of Fortune China official website
Sinopharm Group has 8 consecutive rises! Operating income exceeded the 500 billion mark for the first time Sinopharm official micro-message, this year Sinopharm Group has been included in the Fortune Global 500 list for the 9th consecutive year. Since entering the list for the first time in 2013, Sinopharm Group has continuously improved its ranking and has risen to 337 places so far. 
It is reported that in 2020, the annual operating income of Sinopharm Group will exceed the 500 billion mark for the first time, and the total profit will exceed the 20 billion mark. Compared with the end of the "Twelfth Five-Year Plan", the main indicators such as operating income, total profit, total assets, and owner's equity Both have doubled, and the scale, efficiency, and development speed will continue to maintain the leading position in the industry; in the future, Sinopharm Group will go all out to promote Sinopharm’s “four pillars and eight pillars, one hundred trillion” innovation-driven life The in-depth implementation of the overall development strategy of cycle, entire industry chain, and entire ecosystem will make strides forward on the new journey of building a world-class comprehensive medical and health industry group with global competitiveness!
Guangyao Group's new entry into the list will promote Chinese medicine to the world In addition, Guangzhou Pharmaceutical Group is a new company on the list today. According to the financial report of Guangzhou Pharmaceutical Group, the total revenue of Guangzhou Pharmaceutical Group in 2020 will exceed 150 billion yuan. It is the first Chinese company to enter the world's top 500 companies with traditional Chinese medicine as its main business. In the first quarter of this year, total revenue was 41.582 billion yuan, a year-on-year increase of 18.60%, and total profits were 2.215 billion yuan, a year-on-year increase of 30.70%. As China's largest pharmaceutical company and China's largest proprietary Chinese medicine production base, Guangyao Group's business covers the entire industrial chain of the pharmaceutical industry, including the pharmaceutical industry, pharmaceutical commerce, and medical and health services. Among them, the Chinese medicine business has unique characteristics, with 12 Chinese time-honored Chinese medicine brands and 10 companies with a history of more than 100 years, accounting for half of the time-honored brands in the national pharmaceutical industry. Guangyao Group stated that it will then promote Chinese medicine to the world, and in the next five years, it will focus on building a world-class biomedicine and health enterprise with industrial characteristics and distinctive culture. Information source: public information such as Fortune.com, corporate official WeChat accounts and announcements
August 03, 2021
